AstraZeneca invests $2bn in Summit Therapeutics to co-develop cancer drugs
According to The Guardian Business, AstraZeneca is investing $2 billion in Summit Therapeutics to co-develop and test anti-cancer drugs, with plans to collaborate on a series of studies and to broaden the reach of its ADC portfolio alongside next-generation immunotherapies, including PD-1 targeting bispecifics.
economy2 h ago
